Table 5.
Disease activity and ANCA titers at presentation, treatment and outcome in study groups.
| Patients with idiopathic vasculitides (n = 56) | Patients with antithyroid DIDs (n = 16) | |||||
| WG n = 29 | MPA n = 23 | CSSy n = 4 | WG n = 1 | MPA n = 3 | LLD n = 12 | |
| BVAS | 21.37 | 19.78 | 20.0 | 15 | 13. 0 | - |
| cANCA, n | 28 | 0 | 0 | 1 | 0 | 0 |
| cANCA, l/titer, median | 128 | - | - | 64 | - | - |
| pANCA, n | 1 | 23 | 4 | - | 3 | 12 |
| pANCA,1/titer, median | 64 | 256 | 128 | - | 128 | 256 |
| Cyclophosphamide, n | 29 | 23 | 4 | 1 | 2 | 0 |
| Only corticosteroids n | 0 | 0 | 0 | 0 | 1 | 2 |
| cANCA after 6 months, 1/ titer, median | 16* | - | - | 8 | - | - |
| pANCA after 6 months, 1/titer, median | 8 | 16 | - | - | 32 | 128 |
| CRF, n | 14 | 10 | 1 | 0 | 1 | 0 |
| TRF, n | 2 | 6 | 0 | 0 | 1 | 0 |
| Lethal outcome, n | 11 | 2 | 0 | 0 | 0 | 0 |
| Patients with relapses, n | 23 | 22 | 2 | 0 | 0 | 0 |
*Median titer of 23 WG patients, six died at first presentation. BVAS, Birmingham Vasculitis Activity Score; cANCA, cytoplasmic antineutrophil cytoplasmic antibodies; CRF, chronic renal failure; CSS, Churg Strauss syndrome; DID, drug-induced autoimmune disease; LLD, lupus-like disease; MPA, microscopic polyangiitis; pANCA, perinuclear antineutrophil cytoplasmic antibodies; TRF, terminal renal failure; WG, Wegener's granulomatosis.